The aim of this study was to measure serum allopregnanolone levels and other hormones in women who completed the Female Sexual Function Index (FSFI; Rosen et al., 2000) during the follicular or the luteal phase of the menstrual cycle. Twenty-nine women with a regular menstrual cycle completed the FSFI during days 5-7 and days 19-21 of their menstrual cycles. We collected a blood sample on the same days so that we could determine levels of allopregnanolone (AP), dehydroepiandrosterone (DHEA), free testosterone (FreeT), androstenedione (A), and estradiol (E2); we stored serum at--20 degrees C until we assayed it. We performed statistical analyses by parametric and nonparametric comparisons and correlations, as appropriate. We found that the full FSFI score was 23 +/- 11.3 (mean +/- SD; 31% under 95% confidence interval = 18.7) in our study population. We also found a significant positive correlation between serum allopregnanolone levels and each FSFI domain, including full scale score (r = 0.47, p < 0.01), with the exception of pain. Similarly, we found a positive correlation between FreeT and each FSFI domain and full scale score (r = 0.55, p < 0.002). We found no significant correlation among FSFI scores and DHEA, A, or E2 plasma levels. It is interesting to note that FSFI full score was significantly higher (p < 0.04) in women tested in the luteal phase compared to women tested in the follicular phase. Serum allopregnanolone may be relevant to female sexuality directly or by its influence on a woman's general sense of well-being during the menstrual cycle. Further studies are required to test the hypothesis that high serum allopregnanolone levels in the luteal phase play a role in women's attitudes toward self-report questionnaires on sexual function.

Nappi, R.E., Abbiati, I., Luisi, S., Ferdeghini, F., Polatti, F., & Genazzani, A.R. (2003). Serum allopregnanolone levels relate to FSFI score during the menstrual cycle. JOURNAL OF SEX & MARITAL THERAPY, 29, 95-102 [10.1080/713847135].

Serum allopregnanolone levels relate to FSFI score during the menstrual cycle

LUISI, S.;
2003

Abstract

The aim of this study was to measure serum allopregnanolone levels and other hormones in women who completed the Female Sexual Function Index (FSFI; Rosen et al., 2000) during the follicular or the luteal phase of the menstrual cycle. Twenty-nine women with a regular menstrual cycle completed the FSFI during days 5-7 and days 19-21 of their menstrual cycles. We collected a blood sample on the same days so that we could determine levels of allopregnanolone (AP), dehydroepiandrosterone (DHEA), free testosterone (FreeT), androstenedione (A), and estradiol (E2); we stored serum at--20 degrees C until we assayed it. We performed statistical analyses by parametric and nonparametric comparisons and correlations, as appropriate. We found that the full FSFI score was 23 +/- 11.3 (mean +/- SD; 31% under 95% confidence interval = 18.7) in our study population. We also found a significant positive correlation between serum allopregnanolone levels and each FSFI domain, including full scale score (r = 0.47, p < 0.01), with the exception of pain. Similarly, we found a positive correlation between FreeT and each FSFI domain and full scale score (r = 0.55, p < 0.002). We found no significant correlation among FSFI scores and DHEA, A, or E2 plasma levels. It is interesting to note that FSFI full score was significantly higher (p < 0.04) in women tested in the luteal phase compared to women tested in the follicular phase. Serum allopregnanolone may be relevant to female sexuality directly or by its influence on a woman's general sense of well-being during the menstrual cycle. Further studies are required to test the hypothesis that high serum allopregnanolone levels in the luteal phase play a role in women's attitudes toward self-report questionnaires on sexual function.
Nappi, R.E., Abbiati, I., Luisi, S., Ferdeghini, F., Polatti, F., & Genazzani, A.R. (2003). Serum allopregnanolone levels relate to FSFI score during the menstrual cycle. JOURNAL OF SEX & MARITAL THERAPY, 29, 95-102 [10.1080/713847135].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11365/33205
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo